Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CCXI ChemoCentryx (CCXI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About ChemoCentryx Stock (NASDAQ:CCXI) 30 days 90 days 365 days Advanced Chart Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get ChemoCentryx alerts:Sign Up Key Stats Today's Range$51.99▼$51.9950-Day Range$51.66▼$51.9952-Week Range$14.95▼$52.00Volume113 shsAverage Volume1.68 million shsMarket Capitalization$3.71 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Read More… Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. ChemoCentryx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks15th Percentile Overall ScoreCCXI MarketRank™: ChemoCentryx scored higher than 15% of companies evaluated by MarketBeat, and ranked 897th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ChemoCentryx. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ChemoCentryx are expected to grow in the coming year, from ($1.81) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChemoCentryx is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChemoCentryx is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemoCentryx has a P/B Ratio of 12.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CCXI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChemoCentryx does not currently pay a dividend.Dividend GrowthChemoCentryx does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.75 Short InterestThere is no current short interest data available for CCXI. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added ChemoCentryx to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ChemoCentryx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.30% of the stock of ChemoCentryx is held by insiders.Percentage Held by Institutions81.09% of the stock of ChemoCentryx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ChemoCentryx's insider trading history. Receive CCXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter. Email Address CCXI Stock News HeadlinesRishi Gupta's Net WorthFebruary 22, 2024 | benzinga.comAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX - PR NewswireOctober 20, 2022 | prnewswire.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…November 21, 2024 | Colonial Metals (Ad)AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYXOctober 20, 2022 | finance.yahoo.comChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings - Yahoo FinanceOctober 17, 2022 | finance.yahoo.comChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual MeetingsOctober 17, 2022 | finance.yahoo.comChemoCentryx Inc Shares Close in on 52-Week High - Market Mover - NasdaqOctober 15, 2022 | nasdaq.comChemoCentryx Inc Shares Approach 52-Week High - Market Mover - NasdaqOctober 7, 2022 | nasdaq.comSee More Headlines CCXI Stock Analysis - Frequently Asked Questions How were ChemoCentryx's earnings last quarter? ChemoCentryx, Inc. (NASDAQ:CCXI) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.13. The biopharmaceutical company earned $17.74 million during the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative trailing twelve-month return on equity of 48.52% and a negative net margin of 357.01%. What other stocks do shareholders of ChemoCentryx own? Based on aggregate information from My MarketBeat watchlists, some other companies that ChemoCentryx investors own include Energy Transfer (ET), Gilead Sciences (GILD), Block (SQ), Exelixis (EXEL), Meta Platforms (META), HubSpot (HUBS) and NVIDIA (NVDA). Company Calendar Last Earnings11/08/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:CCXI CUSIP16383L10 CIK1340652 Webwww.chemocentryx.com Phone(650) 210-2900Fax650-210-2910Employees178Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,760,000.00 Net Margins-357.01% Pretax Margin-357.01% Return on Equity-48.52% Return on Assets-30.59% Debt Debt-to-Equity Ratio0.02 Current Ratio4.54 Quick Ratio4.47 Sales & Book Value Annual Sales$32.22 million Price / Sales115.14 Cash FlowN/A Price / Cash FlowN/A Book Value$4.09 per share Price / Book12.71Miscellaneous Outstanding Shares71,356,000Free Float65,433,000Market Cap$3.71 billion OptionableOptionable Beta1.22 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CCXI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChemoCentryx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ChemoCentryx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.